Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial. Park S, Ahn HK, Lee S, Min YJ, et al. J Thorac Oncol 2025;20:1279-1288.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Park S, Ahn HK, Lee S, Min YJ, et al. Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial. J Thorac Oncol 2025;20:1279-1288.
PMID: 40350080